A common strategy to synthesize 4/6-(4-(4-methylpiperazin-1-yl)-6-(4-(4-oxo-2-phenylthiazolidin-3-yl)phenyl)-1,3,5-triazin-2-yloxy)benzonitriles/nicotinonitriles was developed by applying an efficient palladium-catalyzed C–C Suzuki coupling. Moreover, the synthesized compounds were also tested for their in vitro antimycobacterial activity against Mycobacterium tuberculosis H₃₇Rv using BACTEC MGIT and Lowenstein–Jensen MIC methods. Several compounds displayed profound antimycobacterial activity in combination with low toxicity towards mammalian cells. The best results were observed amongst the nicotinonitrile substituted s-triazine analogs and it could be a potential starting point to develop new lead compounds in the fight against M. tuberculosis H₃₇Rv. The newly synthesized compounds were characterized by IR, ¹H NMR, ¹³C NMR, MS and elemental analysis.

合成4 / 6-（4-（4-甲基哌嗪-1-基）-6-（4-（4-氧-2-苯基噻唑烷-3-基）苯基）-1,3,5-三嗪的通用策略通过应用有效的钯催化的CC Suzuki偶联剂开发了-2-基氧基）苄腈/烟腈。此外，还使用BACTEC MGIT和Lowenstein-Jensen MIC方法测试了合成的化合物对结核分枝杆菌H ₃₇ Rv的体外抗分枝杆菌活性。几种化合物具有很强的抗分枝杆菌活性，并且对哺乳动物细胞的毒性低。在烟腈取代的s-三嗪类似物中观察到了最好的结果，这可能是在抗结核药物中开发新的先导化合物的潜在起点。结核分枝杆菌H ₃₇ Rv。通过IR，¹ H NMR，¹³ C NMR，MS和元素分析对新合成的化合物进行表征。